Details of the Drug Combinations

General Information of This Drug (ID: DM7HXWT)

Drug Name
Nilotinib   DM7HXWT
Synonyms
NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)
Indication
Disease Entry ICD 11 Status REF
Chronic myelogenous leukaemia 2A20.0 Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

559 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Nilotinib DCD99J7 ABIRATERONE Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
ABIRATERONE + Nilotinib DCI1LKN ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [2]
ABIRATERONE + Nilotinib DC80G3J ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
ABIRATERONE + Nilotinib DCFF4RO ABIRATERONE Glioma (Cell Line: SF-268) [2]
ABIRATERONE + Nilotinib DCB2Q1K ABIRATERONE Renal cell carcinoma (Cell Line: SN12C) [2]
ABIRATERONE + Nilotinib DC43POE ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
ABIRATERONE + Nilotinib DCXQPZ3 ABIRATERONE Amelanotic melanoma (Cell Line: M14) [4]
ABIRATERONE + Nilotinib DC75MJE ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
ABIRATERONE + Nilotinib DCCFR4Y ABIRATERONE Large cell lung carcinoma (Cell Line: NCI-H460) [4]
ABIRATERONE + Nilotinib DCZB1KN ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [4]
ABIRATERONE + Nilotinib DCYOKLV ABIRATERONE Prostate carcinoma (Cell Line: PC-3) [4]
Amonafide + Nilotinib DCXMU3U Amonafide Adenocarcinoma (Cell Line: HCC-2998) [2]
Amonafide + Nilotinib DCMQBD1 Amonafide Glioblastoma (Cell Line: SNB-75) [2]
Amonafide + Nilotinib DC1JQYC Amonafide Lung adenocarcinoma (Cell Line: HOP-62) [2]
Anastrozole + Nilotinib DCBYWUK Anastrozole Adenocarcinoma (Cell Line: DU-145) [2]
Anastrozole + Nilotinib DCCEY5Y Anastrozole Adenocarcinoma (Cell Line: OVCAR3) [2]
Anastrozole + Nilotinib DCXFXQT Anastrozole Adenocarcinoma (Cell Line: A549) [2]
Anastrozole + Nilotinib DCL1NKJ Anastrozole Adenocarcinoma (Cell Line: HT29) [2]
Anastrozole + Nilotinib DC64XCV Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Anastrozole + Nilotinib DCL25A2 Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Anastrozole + Nilotinib DCOXEL1 Anastrozole Amelanotic melanoma (Cell Line: M14) [2]
Anastrozole + Nilotinib DC1EQVZ Anastrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Anastrozole + Nilotinib DCDNZM0 Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Anastrozole + Nilotinib DCN1HFI Anastrozole Glioma (Cell Line: SF-295) [2]
Anastrozole + Nilotinib DCEQFUQ Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Anastrozole + Nilotinib DCZ54DD Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Anastrozole + Nilotinib DC9W2B5 Anastrozole Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Anastrozole + Nilotinib DC943AL Anastrozole Malignant melanoma (Cell Line: UACC62) [2]
Anastrozole + Nilotinib DCXODC5 Anastrozole Melanoma (Cell Line: MALME-3M) [2]
Anastrozole + Nilotinib DCUTPSZ Anastrozole Melanoma (Cell Line: UACC-257) [2]
Anastrozole + Nilotinib DC0TWNA Anastrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Anastrozole + Nilotinib DCMX5WL Anastrozole Colon adenocarcinoma (Cell Line: COLO 205) [3]
Arfolitixorin + Nilotinib DC7K86Y Arfolitixorin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Arfolitixorin + Nilotinib DCS6CSH Arfolitixorin Adenocarcinoma (Cell Line: A549) [4]
Arfolitixorin + Nilotinib DCP7GPH Arfolitixorin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
BIO-300 + Nilotinib DCW6QSP BIO-300 Glioblastoma (Cell Line: SNB-75) [2]
BIO-300 + Nilotinib DC2NGZC BIO-300 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Bleomycin + Nilotinib DCN7V0R Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Bleomycin + Nilotinib DCQRJG7 Bleomycin Astrocytoma (Cell Line: SNB-19) [2]
Cabazitaxel + Nilotinib DCWODH9 Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [2]
Cabazitaxel + Nilotinib DCJ6DE5 Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [2]
Cabazitaxel + Nilotinib DC6J9WO Cabazitaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Cabazitaxel + Nilotinib DCZCXNY Cabazitaxel Glioblastoma (Cell Line: SNB-75) [2]
Cabazitaxel + Nilotinib DC5KNCW Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Cabazitaxel + Nilotinib DC07HF0 Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [2]
Cabazitaxel + Nilotinib DCOWUA5 Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Nilotinib DCQC60I Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Nilotinib DC2MKY0 Crizotinib Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Nilotinib DCX41HT Crizotinib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Nilotinib DCORTTP Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Crizotinib + Nilotinib DCY7YMI Crizotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Crizotinib + Nilotinib DCEG6Z2 Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Nilotinib DCIK2C7 Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Nilotinib DC10PJU Crizotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Crizotinib + Nilotinib DCDHVW8 Crizotinib Prostate carcinoma (Cell Line: PC-3) [2]
Crizotinib + Nilotinib DC4MB5O Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Nilotinib DCCS4AU Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Dacarbazine + Nilotinib DCG9T13 Dacarbazine Adenocarcinoma (Cell Line: NCIH23) [2]
Dacarbazine + Nilotinib DCJ29YG Dacarbazine Adenocarcinoma (Cell Line: HCT-15) [2]
Dacarbazine + Nilotinib DCHKNGA Dacarbazine Adenocarcinoma (Cell Line: HCT116) [2]
Dacarbazine + Nilotinib DCPX6GC Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Dacarbazine + Nilotinib DC9XJAN Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Dacarbazine + Nilotinib DC8WE67 Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Dacarbazine + Nilotinib DC4K3Y7 Dacarbazine Astrocytoma (Cell Line: SNB-19) [2]
Dacarbazine + Nilotinib DCQU60M Dacarbazine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Dacarbazine + Nilotinib DCYVAZG Dacarbazine Glioma (Cell Line: SF-268) [2]
Dacarbazine + Nilotinib DCP4H2J Dacarbazine Glioma (Cell Line: SF-295) [2]
Dacarbazine + Nilotinib DCNBOLW Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Dacarbazine + Nilotinib DCJBE82 Dacarbazine Lung adenocarcinoma (Cell Line: HOP-62) [2]
Dacarbazine + Nilotinib DCD5F1K Dacarbazine Malignant melanoma (Cell Line: UACC62) [2]
Dacarbazine + Nilotinib DCWUY2H Dacarbazine Colon adenocarcinoma (Cell Line: COLO 205) [3]
Dactinomycin + Nilotinib DCR9AWM Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Dactinomycin + Nilotinib DCGVLUR Dactinomycin Carcinoma (Cell Line: RXF 393) [3]
Dactinomycin + Nilotinib DC7Q41C Dactinomycin Carcinoma (Cell Line: MCF7) [3]
Dactinomycin + Nilotinib DC67T1X Dactinomycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Dactinomycin + Nilotinib DCQRWQ2 Dactinomycin Colon carcinoma (Cell Line: KM12) [3]
Dactinomycin + Nilotinib DCFMU7K Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Dactinomycin + Nilotinib DC967SO Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Dactinomycin + Nilotinib DC34ODN Dactinomycin Adenocarcinoma (Cell Line: DU-145) [4]
Dactinomycin + Nilotinib DCTG67T Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Dactinomycin + Nilotinib DCH2F7D Dactinomycin Adenocarcinoma (Cell Line: NCIH23) [4]
Dactinomycin + Nilotinib DCUMJIM Dactinomycin Adenocarcinoma (Cell Line: A549) [4]
Dactinomycin + Nilotinib DC20RVP Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Dactinomycin + Nilotinib DCV4IQJ Dactinomycin Adenocarcinoma (Cell Line: HT29) [4]
Dactinomycin + Nilotinib DC3PLKW Dactinomycin Adenocarcinoma (Cell Line: SW-620) [4]
Dactinomycin + Nilotinib DCEJQ6F Dactinomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Dactinomycin + Nilotinib DCJMEGJ Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Dactinomycin + Nilotinib DCXP72L Dactinomycin Amelanotic melanoma (Cell Line: M14) [4]
Dactinomycin + Nilotinib DCOZRY5 Dactinomycin Astrocytoma (Cell Line: U251) [4]
Dactinomycin + Nilotinib DCBR369 Dactinomycin Astrocytoma (Cell Line: SNB-19) [4]
Dactinomycin + Nilotinib DCHPRK5 Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Dactinomycin + Nilotinib DCX01HA Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Dactinomycin + Nilotinib DCX85EY Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Dactinomycin + Nilotinib DCPYTQR Dactinomycin Glioblastoma (Cell Line: SNB-75) [4]
Dactinomycin + Nilotinib DC0M6P8 Dactinomycin Glioma (Cell Line: SF-539) [4]
Dactinomycin + Nilotinib DCXSIKW Dactinomycin Glioma (Cell Line: SF-295) [4]
Dactinomycin + Nilotinib DCPI11Z Dactinomycin Glioma (Cell Line: SF-268) [4]
Dactinomycin + Nilotinib DCADYYT Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Dactinomycin + Nilotinib DCFF2OX Dactinomycin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Dactinomycin + Nilotinib DCM8FXY Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Dactinomycin + Nilotinib DCZ7MGM Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Dactinomycin + Nilotinib DCK7KFG Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Dactinomycin + Nilotinib DCCPWCM Dactinomycin Melanoma (Cell Line: MALME-3M) [4]
Dactinomycin + Nilotinib DCY1C4O Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Dactinomycin + Nilotinib DCKIUNT Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Dactinomycin + Nilotinib DCNTSG6 Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Dactinomycin + Nilotinib DCTK8AR Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Dactinomycin + Nilotinib DCEANAZ Dactinomycin Prostate carcinoma (Cell Line: PC-3) [4]
Dexrazoxane + Nilotinib DCC8I1V Dexrazoxane Adenocarcinoma (Cell Line: A549) [4]
Dexrazoxane + Nilotinib DCGGIRY Dexrazoxane Adenocarcinoma (Cell Line: HT29) [4]
Dexrazoxane + Nilotinib DCZM39Z Dexrazoxane Adenocarcinoma (Cell Line: HCT116) [4]
DFN-15 + Nilotinib DCNBZC8 DFN-15 Adenocarcinoma (Cell Line: HT29) [4]
DFN-15 + Nilotinib DCA7PGM DFN-15 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
DFN-15 + Nilotinib DCPRH88 DFN-15 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
DFN-15 + Nilotinib DCWAPQB DFN-15 Lung adenocarcinoma (Cell Line: HOP-62) [4]
DFN-15 + Nilotinib DCM798H DFN-15 Malignant melanoma (Cell Line: LOX IMVI) [4]
Digitoxin + Nilotinib DC0IAFY Digitoxin Adenocarcinoma (Cell Line: OVCAR3) [2]
Digitoxin + Nilotinib DCGK14D Digitoxin Adenocarcinoma (Cell Line: HT29) [2]
Digitoxin + Nilotinib DCXZBKJ Digitoxin Amelanotic melanoma (Cell Line: M14) [2]
Digitoxin + Nilotinib DCH1MIJ Digitoxin Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Digitoxin + Nilotinib DCG3UCK Digitoxin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Digitoxin + Nilotinib DC0ZW8S Digitoxin Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Digitoxin + Nilotinib DCOW5N4 Digitoxin Lung adenocarcinoma (Cell Line: HOP-62) [2]
Digitoxin + Nilotinib DCWOHN2 Digitoxin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Nilotinib DCXR942 Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Nilotinib DCQ9I1C Epirubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Nilotinib DCRGVK6 Epirubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Nilotinib DCSZOHW Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Nilotinib DC06YTC Epirubicin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Nilotinib DCVD9SH Epirubicin Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Nilotinib DC9VP31 Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Nilotinib DCQPFDR Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Nilotinib DCB1CPE Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Nilotinib DCPERFJ Epirubicin Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Nilotinib DCKSHZ3 Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Nilotinib DCSP3LJ Epirubicin Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Nilotinib DC5HPSB Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Nilotinib DCM3X3V Epirubicin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Nilotinib DCXS4LX Epirubicin Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Nilotinib DC5X111 Epirubicin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Nilotinib DC6PCLO Epirubicin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Nilotinib DCQNE9P Epirubicin Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Nilotinib DC6IPWP Epirubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Nilotinib DCZF40V Epirubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Nilotinib DCERP20 Epirubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Nilotinib DCDG5HP Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Nilotinib DCXIFZT Epirubicin Prostate carcinoma (Cell Line: PC-3) [4]
Estramustine + Nilotinib DCP0FVL Estramustine Clear cell renal cell carcinoma (Cell Line: A498) [2]
Estramustine + Nilotinib DCDOFJM Estramustine Adenocarcinoma (Cell Line: HCT116) [4]
Estramustine + Nilotinib DCDDA2O Estramustine Adenocarcinoma (Cell Line: HT29) [4]
Estramustine + Nilotinib DCK3APO Estramustine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Estramustine + Nilotinib DCPS3LA Estramustine Lung adenocarcinoma (Cell Line: HOP-62) [4]
Estramustine + Nilotinib DCXLCEY Estramustine Malignant melanoma (Cell Line: LOX IMVI) [4]
Fludarabine + Nilotinib DCCNVS7 Fludarabine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Fludarabine + Nilotinib DCA31VU Fludarabine Glioma (Cell Line: SF-295) [2]
Fludarabine + Nilotinib DCYS2FU Fludarabine Adenocarcinoma (Cell Line: DU-145) [4]
Fludarabine + Nilotinib DCNAN99 Fludarabine Adenocarcinoma (Cell Line: HT29) [4]
Fludarabine + Nilotinib DCJJWI5 Fludarabine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Fludarabine + Nilotinib DC7LANY Fludarabine Amelanotic melanoma (Cell Line: M14) [4]
Fludarabine + Nilotinib DCLIBWN Fludarabine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Fludarabine + Nilotinib DCHPC1D Fludarabine Lung adenocarcinoma (Cell Line: HOP-62) [4]
FORMESTANE + Nilotinib DCDPPIO FORMESTANE Adenocarcinoma (Cell Line: HT29) [2]
FORMESTANE + Nilotinib DCEPP6I FORMESTANE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
FORMESTANE + Nilotinib DCNVPAU FORMESTANE Amelanotic melanoma (Cell Line: M14) [2]
FORMESTANE + Nilotinib DC8DLYO FORMESTANE Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Gefitinib + Nilotinib DCP4ZKD Gefitinib Adenocarcinoma (Cell Line: HT29) [2]
Gefitinib + Nilotinib DCR6NQY Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Gefitinib + Nilotinib DCX7C2V Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Gefitinib + Nilotinib DCF7B1D Gefitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Gefitinib + Nilotinib DCYAVXK Gefitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Gefitinib + Nilotinib DCHXAP9 Gefitinib Melanoma (Cell Line: MALME-3M) [2]
Gefitinib + Nilotinib DCOS2X4 Gefitinib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Gefitinib + Nilotinib DCCUT6E Gefitinib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Idarubicin + Nilotinib DCW1QWP Idarubicin Adenocarcinoma (Cell Line: HT29) [4]
Idarubicin + Nilotinib DCDY5E9 Idarubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Idarubicin + Nilotinib DCQ2IOS Idarubicin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Imatinib + Nilotinib DCW2V47 Imatinib Adenocarcinoma (Cell Line: HT29) [2]
Imatinib + Nilotinib DCTTI1G Imatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Imatinib + Nilotinib DCVCH18 Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [2]
Imatinib + Nilotinib DCU1J46 Imatinib Lung adenocarcinoma (Cell Line: HOP-62) [2]
Indazole derivative 5 + Nilotinib DC4TWTR Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Indazole derivative 5 + Nilotinib DCB5KEM Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Indazole derivative 5 + Nilotinib DC81TEI Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Indazole derivative 5 + Nilotinib DCD5RTQ Indazole derivative 5 Renal cell carcinoma (Cell Line: SN12C) [2]
Indazole derivative 5 + Nilotinib DC49RWB Indazole derivative 5 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Indazole derivative 5 + Nilotinib DCT2SDA Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Indazole derivative 5 + Nilotinib DCLADWD Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Indazole derivative 5 + Nilotinib DCNWOFG Indazole derivative 5 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Indazole derivative 5 + Nilotinib DCU11K4 Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Indazole derivative 5 + Nilotinib DC9GOG9 Indazole derivative 5 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Indazole derivative 5 + Nilotinib DCL9UK6 Indazole derivative 5 Prostate carcinoma (Cell Line: PC-3) [4]
JNK-IN-8 + Nilotinib DCVTUUG JNK-IN-8 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Nilotinib DCN2RIF JNK-IN-8 Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + Nilotinib DCFVOPC JNK-IN-8 Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + Nilotinib DCF8M2B JNK-IN-8 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Nilotinib DC0V2OF JNK-IN-8 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lenalidomide + Nilotinib DCM2FO4 Lenalidomide Carcinoma (Cell Line: RXF 393) [3]
Lenalidomide + Nilotinib DCSSX18 Lenalidomide Colon adenocarcinoma (Cell Line: COLO 205) [3]
Lenalidomide + Nilotinib DCGJOU7 Lenalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lenalidomide + Nilotinib DCAWVV0 Lenalidomide Melanoma (Cell Line: MALME-3M) [4]
Letrozole + Nilotinib DCP5TTH Letrozole Adenocarcinoma (Cell Line: HT29) [2]
Letrozole + Nilotinib DCQGXQY Letrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Letrozole + Nilotinib DCKZTTG Letrozole Amelanotic melanoma (Cell Line: M14) [2]
Letrozole + Nilotinib DCG7T73 Letrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Letrozole + Nilotinib DC61CHF Letrozole Lung adenocarcinoma (Cell Line: HOP-62) [2]
LIAROZOLE + Nilotinib DCD5W55 LIAROZOLE Carcinoma (Cell Line: RXF 393) [3]
LIAROZOLE + Nilotinib DC2MTBG LIAROZOLE Adenocarcinoma (Cell Line: HT29) [4]
LIAROZOLE + Nilotinib DCZZLC2 LIAROZOLE Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
LIAROZOLE + Nilotinib DCZIEYL LIAROZOLE Lung adenocarcinoma (Cell Line: HOP-62) [4]
LIAROZOLE + Nilotinib DCNYBMJ LIAROZOLE Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Mechlorethamine + Nilotinib DCDMAD1 Mechlorethamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Mechlorethamine + Nilotinib DCIY505 Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Mechlorethamine + Nilotinib DCONJZR Mechlorethamine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Mechlorethamine + Nilotinib DCEPWMM Mechlorethamine Adenocarcinoma (Cell Line: DU-145) [4]
Mechlorethamine + Nilotinib DCBI7G4 Mechlorethamine Adenocarcinoma (Cell Line: HCT-15) [4]
Mechlorethamine + Nilotinib DCBTEH5 Mechlorethamine Adenocarcinoma (Cell Line: HCC-2998) [4]
Methotrexate + Nilotinib DC9EXNL Methotrexate Astrocytoma (Cell Line: U251) [2]
Methotrexate + Nilotinib DCSQ13N Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [2]
Nilotinib + Pentostatin DCCILJC Pentostatin Clear cell renal cell carcinoma (Cell Line: A498) [2]
Nilotinib + Pentostatin DCRP0GR Pentostatin Glioma (Cell Line: SF-539) [2]
Nilotinib + Pentostatin DCRHIVM Pentostatin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Nilotinib + Fulvestrant DCZLFA3 Fulvestrant Glioma (Cell Line: SF-539) [2]
Nilotinib + Lapatinib DCPSOPS Lapatinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Nilotinib + Lapatinib DCDFXBH Lapatinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Nilotinib + Cyclophosphamide DCNTP5T Cyclophosphamide Chronic myelogenous leukemia (Cell Line: K-562) [2]
Nilotinib + Pralatrexate DC9DGAV Pralatrexate Chronic myelogenous leukemia (Cell Line: K-562) [2]
Nilotinib + Pralatrexate DCDSIBN Pralatrexate Glioma (Cell Line: SF-268) [2]
Nilotinib + Terameprocol DCW5ZRZ Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Nilotinib + Ifosfamide DCSITCJ Ifosfamide Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Nilotinib + Docetaxel DCS32ZM Docetaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Nilotinib + Docetaxel DCXMUHT Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [2]
Nilotinib + Docetaxel DCKV56L Docetaxel Astrocytoma (Cell Line: U251) [2]
Nilotinib + Docetaxel DCCLSAT Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [2]
Nilotinib + Docetaxel DC6CCFR Docetaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Nilotinib + Docetaxel DCSR8Y7 Docetaxel Glioblastoma (Cell Line: SNB-75) [2]
Nilotinib + Docetaxel DCNEJFP Docetaxel Glioma (Cell Line: SF-539) [2]
Nilotinib + Docetaxel DC8OL8L Docetaxel Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Nilotinib + Docetaxel DCA4F17 Docetaxel Renal cell carcinoma (Cell Line: SN12C) [2]
Nilotinib + Raloxifene DCXHXMC Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Nilotinib + Raloxifene DCSG3LL Raloxifene Glioma (Cell Line: SF-539) [2]
Nilotinib + Bendamustine hydrochloride DCTLU6G Bendamustine hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Nilotinib + Bendamustine hydrochloride DCIBU0E Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Nilotinib + Bendamustine hydrochloride DCT6O5R Bendamustine hydrochloride Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Nilotinib + Sirolimus DCL8R1N Sirolimus Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Nilotinib + Sirolimus DC1ENA6 Sirolimus Chronic myelogenous leukemia (Cell Line: K-562) [2]
Nilotinib + Sirolimus DC8TLTV Sirolimus Clear cell renal cell carcinoma (Cell Line: A498) [2]
Nilotinib + Sirolimus DC58CJA Sirolimus Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Nilotinib + Mitomycin DCWEZ6F Mitomycin Glioma (Cell Line: SF-295) [2]
Nilotinib + Altretamine DCFGMRR Altretamine Glioblastoma (Cell Line: SNB-75) [2]
Nilotinib + TEM DCXYET5 TEM Astrocytoma (Cell Line: SNB-19) [2]
Nilotinib + Idarubicin DCUO750 Idarubicin Glioblastoma? (Cell Line: T98G) [2]
Nilotinib + Valrubicin DC6PRJQ Valrubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Nilotinib + Valrubicin DC0EWQH Valrubicin Renal cell carcinoma (Cell Line: UO-31) [2]
Nilotinib + Cisplatin DC5BQ18 Cisplatin Clear cell renal cell carcinoma (Cell Line: A498) [2]
Nilotinib + Chlorambucil DCV3Q8U Chlorambucil Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Nilotinib + Chlorambucil DCLBC8M Chlorambucil Glioma (Cell Line: SF-295) [2]
Nilotinib + Sorafenib DC1R1O1 Sorafenib Clear cell renal cell carcinoma (Cell Line: A498) [2]
Nilotinib + ER819762 DCBJAHF ER819762 Clear cell renal cell carcinoma (Cell Line: A498) [2]
Nilotinib + ER819762 DCJCNJ6 ER819762 Glioma (Cell Line: SF-295) [2]
Nilotinib + ER819762 DCYA9FB ER819762 Glioma (Cell Line: SF-268) [2]
Nilotinib + ER819762 DC6MCJ7 ER819762 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Nilotinib + Chloroquine DCKO1QP Chloroquine DD2 (Cell Line: DD2) [2]
Nilotinib + Vinflunine DCICEDA Vinflunine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Nilotinib + Vinflunine DCQMJ9P Vinflunine Chronic myelogenous leukemia (Cell Line: K-562) [2]
Nilotinib + Taxol DCTY7MW Taxol Astrocytoma (Cell Line: U251) [2]
Nilotinib + Taxol DC6VYWA Taxol Glioblastoma (Cell Line: SNB-75) [2]
Nilotinib + Nitisinone DCP8EML Nitisinone DD2 (Cell Line: DD2) [2]
Nilotinib + PMID28870136-Compound-43 DCDM3ZU PMID28870136-Compound-43 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Nilotinib + PMID28870136-Compound-43 DC1H9QW PMID28870136-Compound-43 Anaplastic large cell lymphoma (Cell Line: SR) [2]
Nilotinib + PMID28870136-Compound-43 DCRTJ24 PMID28870136-Compound-43 Astrocytoma (Cell Line: SNB-19) [2]
Nilotinib + PMID28870136-Compound-43 DC34EYI PMID28870136-Compound-43 Clear cell renal cell carcinoma (Cell Line: A498) [2]
Nilotinib + FORMESTANE DCVYE6J FORMESTANE Glioma (Cell Line: SF-268) [2]
Nilotinib + Aminolevulinic Acid Hydrochloride DCWUWFR Aminolevulinic Acid Hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Nilotinib + Aminolevulinic Acid Hydrochloride DCBME2T Aminolevulinic Acid Hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [2]
Nilotinib + Busulfan DCGB4BB Busulfan Astrocytoma (Cell Line: SNB-19) [2]
Nilotinib + Busulfan DCE3PJK Busulfan Glioma (Cell Line: SF-539) [2]
Nilotinib + Fulvestrant DCPAPFJ Fulvestrant Colon carcinoma (Cell Line: KM12) [3]
Nilotinib + Fulvestrant DCQLU8Q Fulvestrant Invasive ductal carcinoma (Cell Line: T-47D) [3]
Nilotinib + Fulvestrant DC7JT0W Fulvestrant Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Nilotinib + Ixabepilone DCS2TFJ Ixabepilone Colon adenocarcinoma (Cell Line: COLO 205) [3]
Nilotinib + Arsenic trioxide DCINO6S Arsenic trioxide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Nilotinib + Pralatrexate DCZQQP2 Pralatrexate Invasive ductal carcinoma (Cell Line: T-47D) [3]
Nilotinib + Pralatrexate DC0G2RW Pralatrexate Invasive ductal carcinoma (Cell Line: BT-549) [3]
Nilotinib + Docetaxel DCGLBEH Docetaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Nilotinib + Docetaxel DC4E0SY Docetaxel Carcinoma (Cell Line: RXF 393) [3]
Nilotinib + Docetaxel DCMYJ6C Docetaxel Colon adenocarcinoma (Cell Line: COLO 205) [3]
Nilotinib + Docetaxel DCIFWPD Docetaxel Colon carcinoma (Cell Line: KM12) [3]
Nilotinib + Docetaxel DCBR5KJ Docetaxel Invasive ductal carcinoma (Cell Line: BT-549) [3]
Nilotinib + Docetaxel DCSWMPB Docetaxel Invasive ductal carcinoma (Cell Line: T-47D) [3]
Nilotinib + Docetaxel DCU6N17 Docetaxel Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Nilotinib + Mitomycin DC0WB05 Mitomycin Colon carcinoma (Cell Line: KM12) [3]
Nilotinib + Vinflunine DC43U6F Vinflunine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Nilotinib + Taxol DC59P66 Taxol Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Nilotinib + Taxol DCEVOEU Taxol Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Nilotinib + Taxol DCX1JG0 Taxol Invasive ductal carcinoma (Cell Line: BT-549) [3]
Nilotinib + PMID28870136-Compound-43 DCV0YCE PMID28870136-Compound-43 Colon carcinoma (Cell Line: KM12) [3]
Nilotinib + PMID28870136-Compound-43 DC67TQO PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Nilotinib + Dasatinib DC0A0XW Dasatinib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Nilotinib + Pentostatin DCCA1Q6 Pentostatin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Nilotinib + Pentostatin DCQT47V Pentostatin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Nilotinib + Pentostatin DCYFR6P Pentostatin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Nilotinib + Pentostatin DCGCZLJ Pentostatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Nilotinib + Pentostatin DCEJQU1 Pentostatin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Nilotinib + Pentostatin DC4XGI6 Pentostatin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Nilotinib + Fulvestrant DC8KFD2 Fulvestrant Adenocarcinoma (Cell Line: OVCAR3) [4]
Nilotinib + Fulvestrant DC7DEIQ Fulvestrant Adenocarcinoma (Cell Line: HCC-2998) [4]
Nilotinib + Fulvestrant DCAJQY9 Fulvestrant Adenocarcinoma (Cell Line: HCT-15) [4]
Nilotinib + Ruxolitinib DCN4BCE Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [4]
Nilotinib + Hepzato DC4S5WQ Hepzato Adenocarcinoma (Cell Line: HT29) [4]
Nilotinib + Cyclophosphamide DCT01XY Cyclophosphamide Adenocarcinoma (Cell Line: OVCAR3) [4]
Nilotinib + Cyclophosphamide DCL4DHD Cyclophosphamide Adenocarcinoma (Cell Line: NCIH23) [4]
Nilotinib + Cyclophosphamide DCYHCN2 Cyclophosphamide Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Nilotinib + Cyclophosphamide DCYAB4I Cyclophosphamide Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Nilotinib + Isoniazid DC1G6IB Isoniazid Lung adenocarcinoma (Cell Line: EKVX) [4]
Nilotinib + Isoniazid DCZ8DRE Isoniazid Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Nilotinib + Arsenic trioxide DCF9O16 Arsenic trioxide Lung adenocarcinoma (Cell Line: HOP-62) [4]
Nilotinib + Pralatrexate DCUEUUC Pralatrexate Adenocarcinoma (Cell Line: DU-145) [4]
Nilotinib + Pralatrexate DCNB118 Pralatrexate Adenocarcinoma (Cell Line: HCT116) [4]
Nilotinib + Pralatrexate DCUIUYZ Pralatrexate Prostate carcinoma (Cell Line: PC-3) [4]
Nilotinib + Terameprocol DCUBNK6 Terameprocol Adenocarcinoma (Cell Line: DU-145) [4]
Nilotinib + Terameprocol DCWSS12 Terameprocol Malignant melanoma (Cell Line: UACC62) [4]
Nilotinib + Ifosfamide DCVDOCL Ifosfamide Lung adenocarcinoma (Cell Line: EKVX) [4]
Nilotinib + Ifosfamide DCWFZ6G Ifosfamide Lung adenocarcinoma (Cell Line: HOP-62) [4]
Nilotinib + Ifosfamide DCF9ZOF Ifosfamide Melanoma (Cell Line: SK-MEL-2) [4]
Nilotinib + Ifosfamide DCXZU8A Ifosfamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Nilotinib + Docetaxel DCJFVHB Docetaxel Adenocarcinoma (Cell Line: DU-145) [4]
Nilotinib + Docetaxel DC9MJYC Docetaxel Adenocarcinoma (Cell Line: OVCAR3) [4]
Nilotinib + Docetaxel DC5I6IX Docetaxel Adenocarcinoma (Cell Line: A549) [4]
Nilotinib + Docetaxel DC4CLFV Docetaxel Adenocarcinoma (Cell Line: NCIH23) [4]
Nilotinib + Docetaxel DC49H1J Docetaxel Adenocarcinoma (Cell Line: HT29) [4]
Nilotinib + Docetaxel DCGCCIV Docetaxel Adenocarcinoma (Cell Line: HCT116) [4]
Nilotinib + Docetaxel DCQYB7D Docetaxel Adenocarcinoma (Cell Line: HCC-2998) [4]
Nilotinib + Docetaxel DCF4TR1 Docetaxel Adenocarcinoma (Cell Line: SW-620) [4]
Nilotinib + Docetaxel DCZX362 Docetaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Nilotinib + Docetaxel DCSES00 Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Nilotinib + Docetaxel DCT273K Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Nilotinib + Docetaxel DCQH9HD Docetaxel Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Nilotinib + Docetaxel DC24U1V Docetaxel Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Nilotinib + Docetaxel DCBR0AQ Docetaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Nilotinib + Docetaxel DCLAANY Docetaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Nilotinib + Raloxifene DCY7BWN Raloxifene Amelanotic melanoma (Cell Line: M14) [4]
Nilotinib + Raloxifene DCN8MUS Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Nilotinib + Raloxifene DC5R34V Raloxifene Malignant melanoma (Cell Line: UACC62) [4]
Nilotinib + Bendamustine hydrochloride DCDEXJ6 Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Nilotinib + Sirolimus DCKKVP9 Sirolimus Adenocarcinoma (Cell Line: OVCAR3) [4]
Nilotinib + Mitomycin DCCFP0Z Mitomycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Nilotinib + Mitomycin DCOGROB Mitomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Nilotinib + Mitomycin DCW02QR Mitomycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Nilotinib + Mitomycin DC9TI6B Mitomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Nilotinib + Mitomycin DCAQ632 Mitomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Nilotinib + Altretamine DCXSTAI Altretamine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Nilotinib + TEM DCK4VYI TEM Melanoma (Cell Line: MALME-3M) [4]
Nilotinib + TEM DC0XY51 TEM Melanoma (Cell Line: SK-MEL-2) [4]
Nilotinib + Bleomycin DCQ0TG9 Bleomycin Adenocarcinoma (Cell Line: HT29) [4]
Nilotinib + Bleomycin DCBJR6F Bleomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Nilotinib + Valrubicin DC3JRIH Valrubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Nilotinib + Valrubicin DCJYR11 Valrubicin Amelanotic melanoma (Cell Line: M14) [4]
Nilotinib + Valrubicin DC50NOO Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Nilotinib + Valrubicin DCZJQ8N Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Nilotinib + Valrubicin DCWYJR4 Valrubicin Lung adenocarcinoma (Cell Line: EKVX) [4]
Nilotinib + Valrubicin DCGAOCY Valrubicin Malignant melanoma (Cell Line: UACC62) [4]
Nilotinib + PD-0173955 DCOED7N PD-0173955 Hepatoblastoma (Cell Line: HB3) [4]
Nilotinib + Cisplatin DC0HR2Z Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Nilotinib + Cisplatin DCJWEBA Cisplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Nilotinib + Cisplatin DCBLWO0 Cisplatin Prostate carcinoma (Cell Line: PC-3) [4]
Nilotinib + Chlorambucil DC90HL9 Chlorambucil Amelanotic melanoma (Cell Line: M14) [4]
Nilotinib + Sorafenib DCA0IG9 Sorafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Nilotinib + Sorafenib DC2X5H6 Sorafenib Melanoma (Cell Line: SK-MEL-2) [4]
Nilotinib + Sorafenib DCKFVDJ Sorafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Nilotinib + ER819762 DCGITK8 ER819762 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Nilotinib + ER819762 DC6ASMW ER819762 Amelanotic melanoma (Cell Line: M14) [4]
Nilotinib + ER819762 DCDGZUF ER819762 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Nilotinib + Chloroquine DCM834H Chloroquine Hepatoblastoma (Cell Line: HB3) [4]
Nilotinib + Pomalidomide DCU18UH Pomalidomide Adenocarcinoma (Cell Line: HCC-2998) [4]
Nilotinib + Pomalidomide DCR8S0K Pomalidomide Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Nilotinib + Vinflunine DCTL5ZN Vinflunine Adenocarcinoma (Cell Line: DU-145) [4]
Nilotinib + Vinflunine DCBYC8N Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [4]
Nilotinib + Vinflunine DCU1BQ4 Vinflunine Adenocarcinoma (Cell Line: SW-620) [4]
Nilotinib + Vinflunine DC6QF9H Vinflunine Adenocarcinoma (Cell Line: HT29) [4]
Nilotinib + Mepacrine DC956KY Mepacrine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Nilotinib + Taxol DCXUS2P Taxol Malignant melanoma (Cell Line: LOX IMVI) [4]
Nilotinib + PMID28870136-Compound-43 DCECQ7S PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT-15) [4]
Nilotinib + PMID28870136-Compound-43 DCP8JWX PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT116) [4]
Nilotinib + PMID28870136-Compound-43 DC4BO1R PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Nilotinib + PMID28870136-Compound-43 DCOU7IC PMID28870136-Compound-43 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Nilotinib + PMID28870136-Compound-43 DCVVORZ PMID28870136-Compound-43 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Nilotinib + Aminolevulinic Acid Hydrochloride DCPTL1Z Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: DU-145) [4]
Nilotinib + Aminolevulinic Acid Hydrochloride DCHLBSK Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: A549) [4]
Nilotinib + Aminolevulinic Acid Hydrochloride DCRLHAS Aminolevulinic Acid Hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Nilotinib + Busulfan DC0KFHQ Busulfan Adenocarcinoma (Cell Line: DU-145) [4]
Nilotinib + Busulfan DCCURTI Busulfan Adenocarcinoma (Cell Line: NCIH23) [4]
Nilotinib + Busulfan DCX423W Busulfan Adenocarcinoma (Cell Line: HCT116) [4]
Nilotinib + Busulfan DCLO7M2 Busulfan Amelanotic melanoma (Cell Line: M14) [4]
Nilotinib + Busulfan DC7VEX6 Busulfan Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Nilotinib + Busulfan DCNWSHD Busulfan Malignant melanoma (Cell Line: LOX IMVI) [4]
Nilotinib + Busulfan DCRTSJ3 Busulfan Prostate carcinoma (Cell Line: PC-3) [4]
Picoplatin + Nilotinib DCYPID5 Picoplatin Glioma (Cell Line: SF-268) [2]
Picoplatin + Nilotinib DC4JSYO Picoplatin Adenocarcinoma (Cell Line: A549) [4]
Picoplatin + Nilotinib DCVUP12 Picoplatin Adenocarcinoma (Cell Line: NCIH23) [4]
Picoplatin + Nilotinib DCBW7SB Picoplatin Adenocarcinoma (Cell Line: HCT116) [4]
Picoplatin + Nilotinib DCCUKQ2 Picoplatin Adenocarcinoma (Cell Line: HCT-15) [4]
Picoplatin + Nilotinib DCQTPUP Picoplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Picoplatin + Nilotinib DC2F68Y Picoplatin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Picoplatin + Nilotinib DCXCL3G Picoplatin Melanoma (Cell Line: SK-MEL-2) [4]
Plicamycin + Nilotinib DCQQJH1 Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Plicamycin + Nilotinib DCZOLEL Plicamycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Plicamycin + Nilotinib DC6OIAY Plicamycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Plicamycin + Nilotinib DCV481J Plicamycin Adenocarcinoma (Cell Line: HCT116) [4]
Plicamycin + Nilotinib DCP6EAN Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Plicamycin + Nilotinib DCMEW1Z Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Plicamycin + Nilotinib DCFD8Y1 Plicamycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Raloxifene + Nilotinib DCUHZFJ Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Raloxifene + Nilotinib DC33ECZ Raloxifene Glioblastoma (Cell Line: SNB-75) [2]
Raloxifene + Nilotinib DCXECFR Raloxifene Glioma (Cell Line: SF-268) [2]
Raloxifene + Nilotinib DC5G1RN Raloxifene Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Raloxifene + Nilotinib DC6OSPL Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Raloxifene + Nilotinib DCENK9K Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [3]
Raloxifene + Nilotinib DCAGSU3 Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Raloxifene + Nilotinib DCUA7KH Raloxifene Adenocarcinoma (Cell Line: HCT116) [4]
Raloxifene + Nilotinib DCM5INF Raloxifene Amelanotic melanoma (Cell Line: M14) [4]
Raloxifene + Nilotinib DC4AXDA Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Raloxifene + Nilotinib DCCKI2O Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Raloxifene + Nilotinib DC90X13 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Raloxifene + Nilotinib DC658RO Raloxifene Malignant melanoma (Cell Line: UACC62) [4]
Raloxifene + Nilotinib DCBYV7G Raloxifene Malignant melanoma (Cell Line: LOX IMVI) [4]
Raloxifene + Nilotinib DCH5P9V Raloxifene Melanoma (Cell Line: SK-MEL-2) [4]
Raloxifene + Nilotinib DCB9XF2 Raloxifene Melanoma (Cell Line: MALME-3M) [4]
Ruxolitinib + Nilotinib DCKZ839 Ruxolitinib Astrocytoma (Cell Line: SNB-19) [2]
Ruxolitinib + Nilotinib DCUKJY9 Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Ruxolitinib + Nilotinib DCW15JY Ruxolitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Ruxolitinib + Nilotinib DCERLNP Ruxolitinib Glioma (Cell Line: SF-539) [2]
Ruxolitinib + Nilotinib DC2B19V Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Ruxolitinib + Nilotinib DCUJF84 Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Ruxolitinib + Nilotinib DCDCDMB Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Ruxolitinib + Nilotinib DC1NDMY Ruxolitinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Ruxolitinib + Nilotinib DC1FRQS Ruxolitinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Ruxolitinib + Nilotinib DC6R9D5 Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Ruxolitinib + Nilotinib DC3Z5HI Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Ruxolitinib + Nilotinib DCQN2Z3 Ruxolitinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Ruxolitinib + Nilotinib DC6OL4J Ruxolitinib Prostate carcinoma (Cell Line: PC-3) [4]
SY-1425 + Nilotinib DCS19JV SY-1425 Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
SY-1425 + Nilotinib DCPCYTY SY-1425 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
SY-1425 + Nilotinib DC35SRQ SY-1425 Adenocarcinoma (Cell Line: HT29) [4]
SY-1425 + Nilotinib DCMY8DR SY-1425 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
SY-1425 + Nilotinib DCXIA2A SY-1425 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Terameprocol + Nilotinib DCO7VA9 Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Terameprocol + Nilotinib DCP4CSY Terameprocol Renal cell carcinoma (Cell Line: SN12C) [2]
Terameprocol + Nilotinib DCJ2XTD Terameprocol Invasive ductal carcinoma (Cell Line: T-47D) [3]
Thioguanine + Nilotinib DCOQIBF Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Thioguanine + Nilotinib DCBKKP2 Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Thioguanine + Nilotinib DCXIS0R Thioguanine Astrocytoma (Cell Line: U251) [2]
Thioguanine + Nilotinib DC7JKYO Thioguanine Astrocytoma (Cell Line: SNB-19) [2]
Thioguanine + Nilotinib DCHVGD4 Thioguanine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Thioguanine + Nilotinib DCICOQB Thioguanine Glioblastoma (Cell Line: SNB-75) [2]
Thioguanine + Nilotinib DCQ3KIC Thioguanine Glioma (Cell Line: SF-539) [2]
Thioguanine + Nilotinib DCFZD4I Thioguanine Glioma (Cell Line: SF-295) [2]
Thioguanine + Nilotinib DCXBU7J Thioguanine Carcinoma (Cell Line: MCF7) [3]
Thioguanine + Nilotinib DCEAUH9 Thioguanine Adenocarcinoma (Cell Line: DU-145) [4]
Thioguanine + Nilotinib DCFX62K Thioguanine Adenocarcinoma (Cell Line: A549) [4]
Thioguanine + Nilotinib DCSOV4G Thioguanine Adenocarcinoma (Cell Line: NCIH23) [4]
Thioguanine + Nilotinib DCAT66X Thioguanine Adenocarcinoma (Cell Line: HT29) [4]
Thioguanine + Nilotinib DC9HP7E Thioguanine Adenocarcinoma (Cell Line: HCT-15) [4]
Thioguanine + Nilotinib DCZTW3J Thioguanine Adenocarcinoma (Cell Line: HCC-2998) [4]
Thioguanine + Nilotinib DC8QC76 Thioguanine Adenocarcinoma (Cell Line: HCT116) [4]
Thioguanine + Nilotinib DC7X1S1 Thioguanine Amelanotic melanoma (Cell Line: M14) [4]
Thioguanine + Nilotinib DCW0XYP Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Thioguanine + Nilotinib DC6OLCN Thioguanine Malignant melanoma (Cell Line: UACC62) [4]
Thioguanine + Nilotinib DCBNBU1 Thioguanine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Topotecan + Nilotinib DCW4NJU Topotecan Carcinoma (Cell Line: MCF7) [3]
Topotecan + Nilotinib DCQPFO9 Topotecan Adenocarcinoma (Cell Line: A549) [4]
Topotecan + Nilotinib DCCZCSR Topotecan Amelanotic melanoma (Cell Line: M14) [4]
Topotecan + Nilotinib DC4Q9SZ Topotecan Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Topotecan + Nilotinib DC2II91 Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Topotecan + Nilotinib DCMJ2AB Topotecan Glioma (Cell Line: SF-268) [4]
Topotecan + Nilotinib DCOXFIQ Topotecan Lung adenocarcinoma (Cell Line: EKVX) [4]
Topotecan + Nilotinib DCQ3D78 Topotecan Melanoma (Cell Line: MALME-3M) [4]
Topotecan + Nilotinib DCEU2HE Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Topotecan + Nilotinib DCGHFAU Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Topotecan + Nilotinib DCAL4DI Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Topotecan + Nilotinib DCXA3WI Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Topotecan + Nilotinib DCYI8YZ Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Topotecan + Nilotinib DCT4GC6 Topotecan Prostate carcinoma (Cell Line: PC-3) [4]
Trifluridine + Nilotinib DCQF591 Trifluridine Glioma (Cell Line: SF-295) [2]
Trifluridine + Nilotinib DCI9HBW Trifluridine Adenocarcinoma (Cell Line: NCIH23) [4]
Trifluridine + Nilotinib DCQ4K7G Trifluridine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Trifluridine + Nilotinib DCQ7S7H Trifluridine Melanoma (Cell Line: MALME-3M) [4]
Trifluridine + Nilotinib DCVU9SI Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Trifluridine + Nilotinib DCPP4UR Trifluridine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Uracil mustard + Nilotinib DCDFZ8Q Uracil mustard Anaplastic large cell lymphoma (Cell Line: SR) [2]
Uracil mustard + Nilotinib DC1ZCOW Uracil mustard Glioblastoma (Cell Line: SNB-75) [2]
Uracil mustard + Nilotinib DCPBSRF Uracil mustard Glioma (Cell Line: SF-295) [2]
Uracil mustard + Nilotinib DCFUZG3 Uracil mustard Adenocarcinoma (Cell Line: HCT116) [4]
Uracil mustard + Nilotinib DCHDI0F Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Vandetanib + Nilotinib DCORHX7 Vandetanib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Nilotinib DCLTHTB Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Nilotinib DCA16JD Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Nilotinib DCCKT5F Vandetanib Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Nilotinib DCSTYHL Vandetanib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Nilotinib DCIYXI9 Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Nilotinib DC4Y4RW Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Nilotinib DC7YDL2 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Nilotinib DCGK7UV Vandetanib Glioma (Cell Line: SF-268) [4]
Vandetanib + Nilotinib DCKP29A Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Nilotinib DCLKO24 Vandetanib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vemurafenib + Nilotinib DCBYKDR Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vemurafenib + Nilotinib DCTXLW3 Vemurafenib Carcinoma (Cell Line: MCF7) [3]
Vemurafenib + Nilotinib DCWLMIQ Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vemurafenib + Nilotinib DC66S7Q Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vemurafenib + Nilotinib DC973SE Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vemurafenib + Nilotinib DCMXYYK Vemurafenib Glioma (Cell Line: SF-268) [4]
Vemurafenib + Nilotinib DCQT8DI Vemurafenib Glioma (Cell Line: SF-539) [4]
Vemurafenib + Nilotinib DCLP7BA Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vemurafenib + Nilotinib DCBDZTW Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Vemurafenib + Nilotinib DCDOS0P Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vemurafenib + Nilotinib DCGEHZ1 Vemurafenib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vemurafenib + Nilotinib DCYEJHW Vemurafenib Melanoma (Cell Line: SK-MEL-2) [4]
Vemurafenib + Nilotinib DCQ3NHP Vemurafenib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vemurafenib + Nilotinib DCW6GLT Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vemurafenib + Nilotinib DC4WMD4 Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vemurafenib + Nilotinib DCIJWAR Vemurafenib Prostate carcinoma (Cell Line: PC-3) [4]
Vincristine + Nilotinib DC65CHW Vincristine Adenocarcinoma (Cell Line: DU-145) [2]
Vincristine + Nilotinib DCZU3PS Vincristine Adenocarcinoma (Cell Line: A549) [2]
Vincristine + Nilotinib DCQ33B9 Vincristine Adenocarcinoma (Cell Line: HT29) [2]
Vincristine + Nilotinib DC92QTD Vincristine Amelanotic melanoma (Cell Line: MDA-MB-435) [2]
Vincristine + Nilotinib DCG9468 Vincristine Amelanotic melanoma (Cell Line: M14) [2]
Vincristine + Nilotinib DCL0QSR Vincristine Astrocytoma (Cell Line: U251) [2]
Vincristine + Nilotinib DC0INED Vincristine Clear cell renal cell carcinoma (Cell Line: A498) [2]
Vincristine + Nilotinib DCRAEEJ Vincristine Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Vincristine + Nilotinib DCAZJNA Vincristine Glioma (Cell Line: SF-539) [2]
Vincristine + Nilotinib DCZPGXX Vincristine Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Vincristine + Nilotinib DC248P8 Vincristine Lung adenocarcinoma (Cell Line: HOP-62) [2]
Vincristine + Nilotinib DC6Z1A6 Vincristine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Vincristine + Nilotinib DCMDZ0G Vincristine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Vincristine + Nilotinib DCVCB0R Vincristine Prostate carcinoma (Cell Line: PC-3) [2]
Vincristine + Nilotinib DC81L1L Vincristine Colon carcinoma (Cell Line: KM12) [3]
Vinflunine + Nilotinib DC92D6G Vinflunine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Vinflunine + Nilotinib DC79JFP Vinflunine Astrocytoma (Cell Line: SNB-19) [2]
Vinflunine + Nilotinib DCVON59 Vinflunine Clear cell renal cell carcinoma (Cell Line: A498) [2]
Vinflunine + Nilotinib DCOCU4S Vinflunine Renal cell carcinoma (Cell Line: UO-31) [2]
Vinflunine + Nilotinib DC2QYOW Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [4]
Vinflunine + Nilotinib DCDCEHV Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vismodegib + Nilotinib DCSR55E Vismodegib Carcinoma (Cell Line: MCF7) [3]
Vismodegib + Nilotinib DCAB494 Vismodegib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vismodegib + Nilotinib DC728C4 Vismodegib Amelanotic melanoma (Cell Line: M14) [4]
Vismodegib + Nilotinib DCL8MLL Vismodegib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vismodegib + Nilotinib DCLNAO6 Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vismodegib + Nilotinib DC468RK Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vismodegib + Nilotinib DCVXWR5 Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vismodegib + Nilotinib DCCB6K4 Vismodegib Glioma (Cell Line: SF-539) [4]
Vismodegib + Nilotinib DCSLANQ Vismodegib Glioma (Cell Line: SF-268) [4]
Vismodegib + Nilotinib DCCLL1F Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vismodegib + Nilotinib DC8EZEB Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vismodegib + Nilotinib DCR9NA8 Vismodegib Lung adenocarcinoma (Cell Line: EKVX) [4]
Vismodegib + Nilotinib DCV8TEB Vismodegib Malignant melanoma (Cell Line: UACC62) [4]
Vismodegib + Nilotinib DCRKQV8 Vismodegib Melanoma (Cell Line: MALME-3M) [4]
Vismodegib + Nilotinib DC18EIQ Vismodegib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vismodegib + Nilotinib DC2PC99 Vismodegib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vismodegib + Nilotinib DCBJV5V Vismodegib Prostate carcinoma (Cell Line: PC-3) [4]
Vismodegib + Nilotinib DCVA26I Vismodegib Renal cell carcinoma (Cell Line: UO-31) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 559 DrugCom(s)
10 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
ABL001 + Nilotinib DC1WI5A ABL001 Chronic Myelogenous Leukemia [5]
Flumatinib + Nilotinib DCB2D5A Flumatinib CML-CP; Mutation;Suboptimal Response or Failure in TKI [6]
Ruxolitinib + Nilotinib DCQMQCX Ruxolitinib Chronic Phase Chronic Myeloid Leukemia [7]
Ruxolitinib + Nilotinib DC7E23V Ruxolitinib Leukemia, Chronic Myeloid [8]
Trametinib + Nilotinib DC82VD5 Trametinib Metastatic Melanoma [9]
Vinblastine + Nilotinib DCUKT29 Vinblastine Refractory Low-grade Gliomas [10]
Nilotinib + Imatinib DCGACF2 Imatinib Leukemia, Myeloid, Chronic [11]
Nilotinib + Imatinib DCY1DG0 Imatinib Chronic Myeloid Leukemia [12]
Nilotinib + Imatinib DCCRTDU Imatinib Leukemia, Chronic Myeloid [13]
Nilotinib + Imatinib DCIMNZR Imatinib Chronyc Myeloid Leukemia [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5697).
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 ClinicalTrials.gov (NCT02081378) A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
6 ClinicalTrials.gov (NCT04681820) Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib
7 ClinicalTrials.gov (NCT01702064) Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
8 ClinicalTrials.gov (NCT02973711) A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
9 ClinicalTrials.gov (NCT04903119) Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
10 ClinicalTrials.gov (NCT01884922) Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults
11 ClinicalTrials.gov (NCT02269267) The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
12 ClinicalTrials.gov (NCT04578847) A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
13 ClinicalTrials.gov (NCT02326311) Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ?0 Years in Deep Molecular Response
14 ClinicalTrials.gov (NCT02602314) Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia